Jason M. Redman, M.D.
Dr. Redman is a physician treating cancer patients with combinations of immunotherapy, chemotherapy and other therapies. He works on clinical trials for patients with prostate cancer, colon cancer, head and neck cancer, and other solid tumors.
The immune system is a complex network traditionally known for fighting infections. However, it can also fight cancer. Cancer immunotherapy refers to drug treatments designed to help the immune system recognize and fight cancer. In some cases, these treatments can lead to significant and long-lasting decreases in cancer burden. Dr. Redman is a member of the Genitourinary Malignancies Branch (GMB) with a Joint Appointment in the Laboratory of Tumor Immunology and Biology (LTIB). He works closely with scientists who study the effects of immunotherapy on cancer in the laboratory. This research guides selection of drug combinations for use in clinical trials.
1) combination immunotherapy for cancer, 2) therapeutic cancer vaccines, 3) colon cancer, 4) prostate cancer, 5) immune checkpoint inhibitors
Center for Cancer Research
National Cancer Institute
Building 10, Room 13N240
Bethesda, MD 20892
Combining immunotherapies and other anti-cancer treatments offers a means to engage (using tumor-targeted vaccines) the body’s immune system and then facilitate the immune system’s attack on the tumor (checkpoint inhibitors, cytokines, immunomodulators, chemotherapy, targeted therapy).
I am interested in applying these techniques to gastrointestinal cancer, head and neck cancer, and prostate cancer. I also conduct phase 1 clinical trials testing new drugs and combinations for any type of solid tumor.
By working closely with the scientists in the Laboratory of Tumor Immunology and Biology (LTIB), the Genitourinary Malignancies Branch (GMB) program aims to use correlative studies to help identify predictors of response to these treatments.
Selected Key Publications
Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment of metastatic castration-resistant prostate cancer.Journal for Immunotherapy of Cancer. 6(1): 91, 2018. [ Journal Article ]
- Expert Review of Anticancer Therapy. 18(8): 719-722, 2018. [ Journal Article ]
- Urologic Oncology. 35(12): 694-700, 2017. [ Journal Article ]
- BioMed Central Medicine. 14: 20, 2016. [ Journal Article ]
- Molecular Immunology. 67(2 Pt A): 28-45, 2015. [ Journal Article ]
Dr. Redman completed his B.S. degree in Philosophy and Biological Sciences at the University of Connecticut. He received his M.D. from New York Medical College. Between the third and fourth years of medical school, Dr. Redman was awarded a 1-year fellowship from the Doris Duke Charitable Research Foundation which he completed at the University of Iowa, Carver College of Medicine. After internal medicine training at Georgetown University Hospital, Dr. Redman completed a medical oncology fellowship at the National Cancer Institute (NCI). Prior to being named Assistant Research Physician, Dr. Redman was awarded the Society for Immunotherapy of Cancer Immunotherapy fellowship at the NCI.
Other awards include the Georgetown Internal Medicine Residency Eric Lemmer, M.D. Memorial Research Award (2016) for excellence in research and scholarly activity, and the New York Medical College Bessie Kaplan Morais Memorial Award (2013) for outstanding interest and ability in scientific investigation. Dr. Redman’s work was selected for podium presentation at the Doris Duke Clinical Research Fellowship Annual Meeting in 2012.